Source comparison
Ipamorelin vs Tesamorelin: Research Comparison
Mechanism of Action Ghrelin receptor agonist (GHSR-1a selective binding) GHRH analogue (anterior pituitary GHRH receptor activation) Ipamorelin works peripherally; tesamorelin centrally through hypothalamic-pituitary axis GH Release Pattern Sharp pulsatile pea
This comparison does not assign a generated winner or score.
- Mechanism of Action
- Ghrelin receptor agonist (GHSR-1a selective binding)
- GHRH analogue (anterior pituitary GHRH receptor activation)
- Ipamorelin works peripherally; tesamorelin centrally through hypothalamic-pituitary axis
- GH Release Pattern
- Sharp pulsatile peaks, 30-45 min to peak, 3-4 hr duration
- Sustained elevation, 30 min to peak, 2-3 hr elevated plateau
- Ipamorelin mimics natural GH pulses; tesamorelin provides broader pharmacological stimulation
- Primary Metabolic Effect
- Lean mass preservation, body recomposition without appetite surge
- Visceral adipose tissue reduction (15.2% VAT decrease in clinical trials)
- Tesamorelin has validated VAT-targeting data; ipamorelin shows recomposition without hyperphagia
- Off-Target Effects
- No cortisol/prolactin elevation, minimal ghrelin-type appetite stimulation
- GH-mediated joint discomfort, peripheral edema (10-13% incidence)
- Ipamorelin cleaner off-target profile; tesamorelin shows predictable GH-related side effects
- Dosing Frequency
- 2-3x daily (200-300mcg per dose)
- Once daily (2mg standard dose)
- Tesamorelin offers simpler once-daily protocol; ipamorelin requires multiple daily doses
- Clinical Trial Data
- Preclinical + limited Phase I/II human data
- Extensive Phase III data in HIV lipodystrophy (>800 subjects)
- Tesamorelin has robust human efficacy/safety dataset; ipamorelin data largely preclinical
- IGF-1 Response
- Variable, dose-dependent, typically requires >600mcg total daily
- Consistent 30-50% elevation at 2mg daily
- Tesamorelin produces more predictable IGF-1 increases for research requiring consistent IGF-1 signaling
- Half-Life
- ~2 hours
- ~26 minutes (despite shorter than ipamorelin, dosed once daily due to sustained pituitary response)
- Both require daily administration; dosing frequency differs due to receptor dynamics
- Research Application Fit
- GH secretagogue receptor studies, sarcopenia models, recomposition without appetite confounds
- Visceral adiposity research, lipodystrophy models, metabolic syndrome investigations
- Select based on primary research outcome: body composition (ipamorelin) vs visceral fat (tesamorelin)